Moreover, 78.9% (15 of 19) of prostate cancer cases exhibited p-Akt (T308) immunoexpression, while 73.6% (14 of 19) of patients exhibited positivity to p-Akt (S473). This evidence concerns the gene AKT1 and prostate carcinoma.